Q2 2025 Achieve Life Sciences Inc Earnings Call Transcript
Key Points
- Achieve Life Sciences Inc (ACHV) successfully submitted a new drug application (NDA) for cytisinicline as a treatment for nicotine dependence to the FDA.
- The company secured a strategic commercial partnership with Omnicom, a leader in healthcare marketing, to support the commercial launch strategy.
- Achieve Life Sciences Inc (ACHV) completed a $49 million capital raise, strengthening its financial position to reach critical milestones in 2026.
- The NDA submission is supported by data from over 2,000 clinical trial participants, demonstrating cytisinicline's efficacy, safety, and tolerability.
- Achieve Life Sciences Inc (ACHV) has a clear path to launch cytisinicline in late 2026, with preparations for availability, access, and awareness well underway.
- The company faces the challenge of launching a new drug as a small company, which is often seen as a high-risk endeavor.
- There is uncertainty regarding the FDA's review timeline, with the company hoping for a priority review but anticipating a standard review.
- Achieve Life Sciences Inc (ACHV) must manage a disciplined approach to commercial investment, balancing pre-commercial activities with financial prudency.
- The synthetic version of cytisinicline is still under development, with no immediate updates on its progress.
- Partnership discussions, particularly for comorbid conditions like COPD, have not progressed significantly as the focus remains on the NDA submission.
Greetings, and welcome to the Achieve Life Sciences second quarter 2025 earnings conference call and Webcast. As a reminder, this conference is being recorded.
I would now like to turn the call over to Nicole Jones, Achieve Investor Relations. Thank you. You may begin.
Thank you, operator. Good morning, everyone, and thank you for joining us today. From Achieve Life Sciences, we are joined by Rick Stewart, Chief Executive Officer; Dr. Cindy Jacobs, President and Chief Medical Officer; Jaime Xinos, Chief Commercial Officer; and Mark Oki, Chief Financial Officer. The management team will be available for Q&A following the prepared remarks. A replay will be available later today using the information in the earnings press release or by visiting the Achieve website.
Today's conference call will contain certain forward-looking statements, including statements regarding the goals, strategies, beliefs, expectations and future potential operating results of Achieve. Although management
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
